Literature DB >> 20811333

Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy.

Mai T Vuong1, Mirjana Hahn-Zoric, Sigrid Lundberg, Iva Gunnarsson, Cees van Kooten, Lars Wramner, Maria Seddighzadeh, Anders Fernström, Lars Å Hanson, Lieu Thi Do, Stefan H Jacobson, Leonid Padyukov.   

Abstract

The Fc-α receptor (FcαR/CD89) is involved in IgA complex formation and may affect the development of IgA nephropathy (IgAN). In this study, we tested the genetic variations of the CD89 gene in relation to disease susceptibility in IgAN and the expression of soluble CD89 (sCD89) in sera of patients with IgAN and in controls. There was a significant difference between the levels of sCD89-IgA complexes, measured by sandwich enzyme-linked immunosorbent assay (ELISA), in 177 patients with IgAN with and without disease progression at the time of first diagnosis. No such difference was found in 42 patients with other renal diseases. The patients with IgAN without disease progression had stable but high levels of sCD89 over 5-15 years of follow-up in contrast to stable but low levels of sCD89 in the disease progression group. Moreover, levels of sCD89 complexes were correlated with one of the five CD89 genetic variants in 212 patients with IgAN and 477 healthy Caucasians; the single-nucleotide polymorphism (SNP) rs11084377 was significantly associated with a lower expression of sCD89. However, no association between CD89 gene polymorphisms and susceptibility to IgAN was detected. Thus, we found an association between the levels of sCD89-IgA complexes in serum and the severity of IgAN, and a possible genetic component in regulating the production or expression of sCD89.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811333     DOI: 10.1038/ki.2010.314

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  33 in total

Review 1.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

Review 2.  Immunoglobulin A nephropathy: a pathophysiology view.

Authors:  Rafaela Cabral Gonçalves Fabiano; Sérgio Veloso Brant Pinheiro; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2016-06-28       Impact factor: 4.575

3.  FcαRI binding at the IgA1 CH2-CH3 interface induces long-range conformational changes that are transmitted to the hinge region.

Authors:  Monica T Posgai; Sam Tonddast-Navaei; Manori Jayasinghe; George M Ibrahim; George Stan; Andrew B Herr
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 11.205

4.  Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.

Authors:  Laureline Berthelot; Thomas Robert; Vincent Vuiblet; Thierry Tabary; Antoine Braconnier; Moustapha Dramé; Olivier Toupance; Philippe Rieu; Renato C Monteiro; Fatouma Touré
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

Review 5.  Pathogenesis of IgA nephropathy.

Authors:  Kar Neng Lai
Journal:  Nat Rev Nephrol       Date:  2012-03-20       Impact factor: 28.314

Review 6.  Treatment of IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2013-04-02       Impact factor: 28.314

7.  Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-01-06

8.  IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

Authors:  Sebastian M Lechner; Lilia Abbad; Erwan Boedec; Christina Papista; Marie-Bénédicte Le Stang; Christelle Moal; Julien Maillard; Agnès Jamin; Julie Bex-Coudrat; Yong Wang; Aiqun Li; Paolo G V Martini; Renato C Monteiro; Laureline Berthelot
Journal:  J Am Soc Nephrol       Date:  2016-02-05       Impact factor: 10.121

9.  Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy.

Authors:  Pei Chen; Guizhen Yu; Xue Zhang; Xinfang Xie; Jinwei Wang; Sufang Shi; Lijun Liu; Jicheng Lv; Hong Zhang
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-11       Impact factor: 8.237

Review 10.  Markers for the progression of IgA nephropathy.

Authors:  Dita Maixnerova; Colin Reily; Qi Bian; Michaela Neprasova; Jan Novak; Vladimir Tesar
Journal:  J Nephrol       Date:  2016-05-03       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.